Ranbaxy Also Could Face Probe By Indian Authorities
This article was originally published in PharmAsia News
Ranbaxy Laboratories not only faces an investigation in the U.S., it also could become the subject of a probe at home in India. Indian authorities have raised questions about whether Ranbaxy's stockholders were informed about U.S. FDA allegations that the firm marketed adulterated generics. Indian authorities are expected to review the same documents requested by U.S. authorities, to see if the company adequately informed shareholders of the financial risks involved in the investigation. (Click here for more
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.